325 related articles for article (PubMed ID: 24346811)
41. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
Janicak PG; Wu JH; Mao L
Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
[TBL] [Abstract][Full Text] [Related]
42. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.
Si T; Shu L; Liu Y; Su YA; Guo C; Zhang H
Hum Psychopharmacol; 2010 Jul; 25(5):404-9. PubMed ID: 20589922
[TBL] [Abstract][Full Text] [Related]
43. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
45. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
[TBL] [Abstract][Full Text] [Related]
48. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
49. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
[TBL] [Abstract][Full Text] [Related]
50. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K
Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427
[TBL] [Abstract][Full Text] [Related]
51. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
[TBL] [Abstract][Full Text] [Related]
52. Paliperidone for schizophrenia.
Dolder C; Nelson M; Deyo Z
Am J Health Syst Pharm; 2008 Mar; 65(5):403-13. PubMed ID: 18281731
[TBL] [Abstract][Full Text] [Related]
53. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
Sliwa JK; Bossie CA; Ma YW; Alphs L
Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
[TBL] [Abstract][Full Text] [Related]
54. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.
Lai YC; Huang MC; Chen CH; Tsai CJ; Pan CH; Chiu CC
Psychiatry Clin Neurosci; 2009 Aug; 63(4):440-8. PubMed ID: 19457210
[TBL] [Abstract][Full Text] [Related]
56. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.
Rodríguez-Martínez A; Quilo CG
Clin Drug Investig; 2013 Dec; 33(12):867-76. PubMed ID: 24241935
[TBL] [Abstract][Full Text] [Related]
57. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
Jones A
J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
[TBL] [Abstract][Full Text] [Related]
58. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
[TBL] [Abstract][Full Text] [Related]
59. Paliperidone: quo vadis?
Citrome L
Int J Clin Pract; 2007 Apr; 61(4):653-62. PubMed ID: 17343660
[TBL] [Abstract][Full Text] [Related]
60. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
